<DOC>
	<DOCNO>NCT01817582</DOCNO>
	<brief_summary>This study conduct investigate safety , comfort , tolerability 3 treatment : Lotemax® gel 0.5 % administered twice daily ( BID ) without Restasis 0.05 % administer BID , Restasis 0.05 % treatment alone 12 week follow-up safety visit 1 week post-treatment . This study also investigate relative efficacy Lotemax gel 0.5 % administer BID without Restasis 0.05 % treatment administer BID Restasis 0.05 % treatment alone reduction clinical sign symptom keratoconjunctivitis sicca ( DED ) first 4 week 12-week Treatment Period end 12-week Treatment Period .</brief_summary>
	<brief_title>Lotemax® Gel 0.5 % Restasis 0.05 % Subjects With Mild Moderate Keratoconjunctivitis Sicca</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Have diagnose treat keratoconjunctivitis sicca ( dry eye disease [ DED ] ) within 6 month prior Visit 1 . Have baseline ( Visit 2 ) Intraocular pressure ( IOP ) measurement ≥ 5 mmHg ≤ 22 mmHg eye , without antiglaucoma therapy . Have mild moderate DED one eye eye Visit 1 Visit 2 . Have know hypersensitivity corticosteroid , cyclosporine , fluorescein , lissamine green , topical anesthetic , component either study drug . Have severe DED . Have corneal erosive disease condition suggestive extensive damage cornea . Have history elevate IOP , history glaucoma , IOP &gt; 22 mm Hg either eye screen visit ( Visit 1 ) . Have penetrate intraocular surgery past 12 month require penetrate intraocular surgery study . Have eyelid surgery within 6 month prior Visit 1 DED secondary surgery . Have visible evidence anterior lid Demodex spp . infection infestation Have corneal refractive surgery corneal transplantation . Have congenitally absent lacrimal meibomian gland obstructive disease lacrimal gland , sarcoidosis , lacrimal gland deficiency . Have diagnosis ongoing ocular infection , active anterior blepharitis , moderate severe pinguecula , StevensJohnson syndrome , ocular cicatricial pemphigoid , significant conjunctival scarring , ocular chemical burn , ocular neurotrophic keratitis . Have serious systemic disease uncontrolled medical condition judgment investigator could confound study assessment limit compliance . Have history ocular herpetic keratitis active blepharitis 4 week prior first dose . Have ocular surgery ( include laser ) within 6 month prior first Treatment Period , plan require ocular surgery study . Neodymiumdoped : yttrium aluminum garnet ( Nd : YAG ) laser posterior capsulotomy allow .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Dry Eye Disease</keyword>
</DOC>